A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform

Recent treatments of leukemias with chimeric antigen receptor (CAR) expressing T cells underline their impressive therapeutic potential. However, once adoptively transferred into patients, there is little scope left to shut them down after elimination of tumor cells or in case adverse side effects o...

Full description

Bibliographic Details
Main Authors: Susann Albert, Claudia Arndt, Anja Feldmann, Ralf Bergmann, Dominik Bachmann, Stefanie Koristka, Florian Ludwig, Pauline Ziller-Walter, Alexandra Kegler, Sebastian Gärtner, Marc Schmitz, Armin Ehninger, Marc Cartellieri, Gerhard Ehninger, Hans-Jürgen Pietzsch, Jens Pietzsch, Jörg Steinbach, Michael Bachmann
Format: Article
Language:English
Published: Taylor & Francis Group 2017-04-01
Series:OncoImmunology
Subjects:
car
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1287246